Correspondence 0001140361-23-019320 from GALECTIN THERAPEUTICS INC (GALT)

GALECTIN THERAPEUTICS INC
Date: April 20, 2023 · CIK: 0001133416 · Accession: 0001140361-23-019320

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-271278

Date

April 20, 2023

Author

Joel Lewis

Form

CORRESP

Company

GALECTIN THERAPEUTICS INC

Letter

RE:

April 20, 2023

VIA EDGAR

Division of Corporation Finance

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention: Arzhang Navai

Galectin Therapeutics Inc.

Registration Statement on Form S-3

File No. 333-271278

Filed April 14, 2023

In accordance with Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Galectin Therapeutics Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to Monday, April 24, 2023 at 4:00 p.m., Eastern Time, or as soon as thereafter practicable.

Please call Brian Lee of Dentons US LLP at (212) 768-6926 to confirm the effectiveness of the Registration Statement or with any questions.

Very truly yours,
Galectin Therapeutics Inc.

Show Raw Text

CORRESP
1
filename1.htm

      April 20, 2023

      VIA EDGAR

      Division of Corporation Finance

      Securities and Exchange Commission

      100 F Street, N.E.

      Washington, D.C. 20549

      Attention: Arzhang Navai

              RE:

              Galectin Therapeutics Inc.

              Registration Statement on Form S-3

              File No. 333-271278

              Filed April 14, 2023

      In accordance with Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Galectin
        Therapeutics Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to Monday, April 24, 2023 at 4:00 p.m., Eastern Time, or as
        soon as thereafter practicable.

      Please call Brian Lee of Dentons US LLP at (212) 768-6926 to confirm the effectiveness of the Registration Statement or with any
        questions.

              Very truly yours,

              Galectin Therapeutics Inc.

              /s/ Joel Lewis

              Joel Lewis

              Chief Executive Officer

          cc:     Brian Lee, Dentons US LLP

SecProbe.io